Citadel Advisors
RLAY icon

Citadel Advisors’s Relay Therapeutics RLAY Stock Holding History

Citadel Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,900
Closed -$77.8K – 13852
2025
Q3 		$77.8K Sell
14,900
-21,200
-59% -$80.8K ﹤0.01% 11991
2025
Q2 		$125K Buy
36,100
+4,400
+14% +$13.1K ﹤0.01% 11128
2025
Q1 		$83.1K Buy
31,700
+16,100
+103% +$63.1K ﹤0.01% 11720
2024
Q4 		$64.3K Sell
15,600
-2,000
-11% -$10.9K ﹤0.01% 12099
2024
Q3 		$125K Buy
17,600
+17,000
+2,833% +$127K ﹤0.01% 10824
2024
Q2 		$3.91K Sell
600
-1,100
-65% -$7.52K ﹤0.01% 13530
2024
Q1 		$14.1K Sell
1,700
-5,600
-77% -$54.6K ﹤0.01% 13257
2023
Q4 		$80.4K Sell
7,300
-3,400
-32% -$28.7K ﹤0.01% 11221
2023
Q3 		$90K Sell
10,700
-10,700
-50% -$115K ﹤0.01% 11026
2023
Q2 		$269K Sell
21,400
-47,500
-69% -$591K ﹤0.01% 9279
2023
Q1 		$1.13M Buy
68,900
+68,700
+34,350% +$1.23M ﹤0.01% 6497
2022
Q4 		$2.99K Sell
200
-11,200
-98% -$214K ﹤0.01% 14264
2022
Q3 		$255K Buy
+11,400
New +$250K ﹤0.01% 9927
2021
Q4 		– Sell
-16,000
Closed -$504K – 14601
2021
Q3 		$504K Buy
+16,000
New +$539K ﹤0.01% 9841

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors's RLAY Position: Q1 2026 in Review

Citadel Advisors increased its Relay Therapeutics (RLAY) stake by 54% in Q1 2026, buying an estimated $556K and bringing the position to 176,265 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #6366.

Citadel Advisors first reported a position in RLAY in Q3 2020 and has held it in 21 quarters since. The position peaked at $20.6M in Q3 2024. 242 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Citadel Advisors held 176,265 shares of Relay Therapeutics worth $1.75M as of Q1 2026.
  • Citadel Advisors bought 62,122 Relay Therapeutics shares in Q1 2026, an estimated $556K.
  • Relay Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6366 holding.
  • Citadel Advisors first reported a position in Relay Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Relay Therapeutics position peaked at $20.6M in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.